c-MYC Antikörper

Produktnummer ABIN967320

Dieses Anti-c-MYC-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von c-MYC in WB, IHC (p), IHC (fro) und FM. Geeignet für Human. Dieses Primary Antibody wurde in 10+ Publikationen zitiert.

Kurzübersicht für c-MYC Antikörper (ABIN967320)

Target: c-MYC (MYC) (Myc Proto-Oncogene protein (MYC))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser c-MYC Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Fluorescence Microscopy (FM)

Klon: 9E10

Produktdetails anti-c-MYC Antikörper

Marke: BD Pharmingen™

Produktmerkmale: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Human c-Myc Peptide

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: It is particularly useful for western blot analysis of myc-tagged recombinant proteins, and recombinant c-myc. Jurkat control lysate [50 µg (1 µg/µl)] is provided as a western blot positive control (store lysate at -20 °C). Additional control lysate is sold separately.

Kommentare:

Related Products: ABIN968537, ABIN967389

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1.0 mg/mL

Buffer: Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store undiluted at -20° C.

Referenzen für anti-c-MYC Antikörper (ABIN967320)

Liu, Hsu, Goeddel, Karin: "Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death." in: Cell, Vol. 87, Issue 3, pp. 565-76, (1996) (PubMed).

Lukas, Parry, Aagaard, Mann, Bartkova, Strauss, Peters, Bartek: "Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16." in: Nature, Vol. 375, Issue 6531, pp. 503-6, (1995) (PubMed).

Royds, Sharrard, Wagner, Polacarz: "Cellular localisation of c-myc product in human colorectal epithelial neoplasia." in: The Journal of pathology, Vol. 166, Issue 3, pp. 225-33, (1992) (PubMed).

Tosca, Linardopoulos, Malliri, Hatziolou, Nicolaidou, Spandidos: "Implication of the ras and myc oncoproteins in the pathogenesis of mycosis fungoides." in: Anticancer research, Vol. 11, Issue 4, pp. 1433-8, (1992) (PubMed).

Blackwood, Eisenman: "Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc." in: Science (New York, N.Y.), Vol. 251, Issue 4998, pp. 1211-7, (1991) (PubMed).

DePinho, Schreiber-Agus, Alt: "myc family oncogenes in the development of normal and neoplastic cells." in: Advances in cancer research, Vol. 57, pp. 1-46, (1991) (PubMed).

Gosney, Field, Gosney, Lye, Spandidos, Butt: "c-myc oncoprotein in bronchial carcinoma: expression in all major morphological types." in: Anticancer research, Vol. 10, Issue 3, pp. 623-8, (1990) (PubMed).

Karayiannis, Yiagnisis, Papadimitriou, Field, Spandidos: "Evaluation of the ras and myc oncoproteins in benign gastric lesions." in: Anticancer research, Vol. 10, Issue 5A, pp. 1127-33, (1990) (PubMed).

Spandidos, Yiagnisis, Papadimitriou, Field: "ras, c-myc and c-erbB-2 oncoproteins in human breast cancer." in: Anticancer research, Vol. 9, Issue 5, pp. 1385-93, (1990) (PubMed).

Evan, Lewis, Ramsay, Bishop: "Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product." in: Molecular and cellular biology, Vol. 5, Issue 12, pp. 3610-6, (1986) (PubMed).

Details zu c-MYC

Target: c-MYC (MYC) (Myc Proto-Oncogene protein (MYC))

Andere Bezeichnung: c-Myc

Hintergrund: The myc gene family contains at least seven closely related genes, c-myc, N-myc, L-myc, P-myc, R-myc, S-myc, and B-myc. C-myc plays a role in proliferation, transformation, and differentiation. It is expressed during embryonic development, in a wide variety of adult tissues, and is amplified in many tumors, particularly lung, breast, cervical and colon carcinomas. Cellular localization has been described as nuclear and/or cytopasmic. C-myc has three sequence motifs in the carboxy terminus, a leucine zipper, a helix-loop-helix, and a basic region. It forms sequence-specific (CACGTG) DNA binding heterodimers with max, a helixloop-helix/leucine zipper protein. Both the leucine zipper domain and the helixloop-helix motif of c-myc contribute to heterodimer formation. DNA binding of myc-max dimers results in a conformational change of the DNA and transcriptional activation. C-myc migrates at 62 kDa in SDS-PAGE. Clone 9E10 recognizes human c-myc. A synthetic peptide corresponding to a C-terminal epitope of the human c-myc protein (AEEQKLISEEDL) was used as an immunogen.

Pathways: p53 Signalweg, Zellzyklus, Sensory Perception of Sound, Transition Metal Ion Homeostasis, Mitotic G1-G1/S Phases, Positive Regulation of Endopeptidase Activity, Regulation of Carbohydrate Metabolic Process, Positive Regulation of Response to DNA Damage Stimulus, Warburg Effekt